TY  - JOUR
AU  - Sosa-Henríquez, Manuel
AU  - Torregrosa, Oscar
AU  - Déniz, Alejandro
AU  - Saavedra, Pedro
AU  - Ortego, Norberto
AU  - Turrión, Ana
AU  - Pérez Castrillón, José Luis
AU  - Díaz-Curiel, Manuel
AU  - Gómez-Alonso, Carlos
AU  - Martínez, Guillermo
AU  - Antonio Blázquez, José
AU  - Olmos-Martínez, José Manuel
AU  - Etxebarria, Íñigo
AU  - Caeiro, José Ramón
AU  - Mora-Peña, Damián
PY  - 2021
DO  - 10.1111/ijcp.14550
UR  - http://hdl.handle.net/10668/18019
T2  - International journal of clinical practice
AB  - Denosumab is a monoclonal antibody approved for the treatment of postmenopausal osteoporosis. The withdrawal of denosumab produces an abrupt loss of bone mineral density and may cause multiple vertebral fractures (MVF). The objective of this study is...
LA  - en
KW  - Bone Density
KW  - Bone Density Conservation Agents
KW  - Denosumab
KW  - Female
KW  - Humans
KW  - Osteoporosis, Postmenopausal
KW  - Osteoporotic Fractures
KW  - Spinal Fractures
TI  - Multiple vertebral fractures after suspension of denosumab. A series of 56 cases.
TY  - research article
VL  - 75
ER  -